Abstract
Objectives
To determine the utility of amide proton transfer-weighted (APTw) MR imaging in distinguishing solitary brain metastases (SBMs) from glioblastomas (GBMs).
Methods
Forty-five patients with SBMs and 43 patients with GBMs underwent conventional and APT-weighted sequences before clinical intervention. The APTw parameters and relative APTw (rAPTw) parameters in the tumour core and the peritumoral brain zone (PBZ) were obtained and compared between SBMs and GBMs. The receiver-operating characteristic (ROC) curve was used to assess the best parameter for distinguishing between the two groups.
Results
The APTwmax, APTwmin, APTwmean, rAPTwmax, rAPTwmin or rAPTwmean values in the tumour core were not significantly different between the SBM and GBM groups (P = 0.141, 0.361, 0.221, 0.305, 0.578 and 0.448, respectively). However, the APTwmax, APTwmin, APTwmean, rAPTwmax, rAPTwmin or rAPTwmean values in the PBZ were significantly lower in the SBM group than in the GBM group (P < 0.001). The APTwmin values had the highest area under the ROC curve 0.905 and accuracy 85.2% in discriminating between the two neoplasms.
Conclusion
As a noninvasive imaging method, APT-weighted MR imaging can be used to distinguish SBMs from GBMs.
Key Points
• APTw values in the tumour core were not different between SBMs and GBMs.
• APTw values in peritumoral brain zone were lower in SBMs than in GBMs.
• The APTw min was the best parameter to distinguish SBMs from GBMs.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
Introduction
According to the West China Glioma Center (WCGC) and Central Brain tumour Registry of the United States (CBTRUS), metastasis and glioma are the most frequent malignant brain neoplasms, and the incidence rate of both diseases has been increasing in recent decades [1, 2]. The ability to distinguish metastases from glioma is critical because the therapeutic planning and follow-up of these tumours are vastly different [3]. If metastasis is suspected, high-dose Gd should be used to elucidate other metastases in the brain [4], and other parts of the body should be examined. For metastasis therapy, nonsurgical treatment is preferred over conventional surgical resection [5]. However, when glioma is suspected, various advanced MRI techniques are required to detect the true tumour margin, and surgical resection is the first choice [6]. Usually, differentiation between the two neoplasms depends primarily on clinical history, particularly in cases with multiple lesions. However, if the patient’s clinical history is uncertain, or the lesion is solitary, the distinction of these neoplasms may be difficult [7]. On conventional MRI, there is substantial overlap between the images of solitary brain metastases (SBMs) and glioblastomas (GBMs), as both manifest similar signal features and contrast enhancement patterns. Previously, investigators worldwide used DWI, PWI, MRS and ASL perfusion imaging to differentiate between these tumours [8,9,10,11]. However, the distinction between these two types of tumours still has limited diagnostic specificity.
Amide proton transfer-weighted (APTw) MR imaging was invented by Zhou and van Zijl et al. and is a novel molecular MRI technique based on chemical exchange-based saturation transfer (CEST), which was designed to detect amide protons of endogenous low-concentration mobile proteins and peptides in tissue [12,13,14]. This technique does not require the use of exogenous contrast agents and is applied to imaging through the exchange between amide protons of mobile proteins and peptides and protons of bulk water. The APTw signals are mainly related to cell density and endogenous mobile proteins and peptides [15,16,17,18]. APTw imaging has emerged as a valuable tool for grading brain tumours [18,19,20] and other cancers that occur in the prostate [21], breast [22, 23] and neck [24, 25]; for distinguishing tumour recurrence from radiation necrosis [26], distinguishing pseudo-progression from true progression in gliomas [27] and differentiating between primary central nervous system lymphomas and glioma [15]; and for characterising cerebral ischaemia [28,29,30]and Parkinson’s disease [31]. However, this technique has not been used to compare SBMs and GBMs. Therefore, the purpose of this study was to evaluate the usefulness of APTw MRI in distinguishing SBMs from GBMs at the molecular level based on their APTw values.
Materials and methods
Study population
The institutional review board of our hospital approved this study, and each patient signed the consent form. From May 2011 to October 2016, 94 patients with SBMs or GBMs were recruited and received conventional and APTw MRI. Data from six patients were excluded because of insufficient image quality due to motion artefacts. Therefore, 88 patients were included in this study. Forty-five patients (33 males, 12 females; age range, 30-74 years; mean age, 56.5 ± 9.2 years) had SBMs confirmed by histopathology (n = 39) or clinical diagnosis (n = 6). The primary sites of cancers included the lung (n = 28), breast (n = 6), kidney (n = 4), colon (n = 4), liver (n = 2) and the lymphatic system (n = 1), and 43 patients (29 males, 14 females; age range, 18-71 years; mean age, 44.8 ± 13.8 years) had GBMs confirmed by histopathology.
MR imaging
All patients underwent a conventional brain MRI sequence and two-dimensional (2D) APTw sequence on a 3.0-T MRI scanner (Achieva 3.0 T; Philips Medical Systems, Best, The Netherlands) before clinical intervention. A body coil was used for radiofrequency (RF) transmission, and a 16-channel head coil was used for signal reception. Conventional MRI sequences included T1-weighted [repetition time (ms)/echo time (ms), 400/20], T2-weighted [repetition time (ms)/echo time (ms), 2800/105] and fluid-attenuated inversion recovery [FLAIR, repetition time (ms)/echo time (ms)/inversion recovery time (ms) 8000/204/2200]. Then, a contrast agent (Gd-DTPA; 0.2 ml/kg body weight; Magnevist; Bayer Schering, Guangzhou, China) was injected through the median cubital vein, and gadolinium-enhanced T1-weighted images were acquired. Other imaging parameters were as follows: field of view, 240 × 240 mm2; slice thickness, 5 mm; gap, 2 mm; matrix, 512 × 512.
The 2D fat-suppressed, fast spin-echo APTw pulse sequence was performed at one T2-weighted image slice showing the maximum area of the tumour before the Gd-T1-weighted image. For saturation, a pulse-train radiofrequency saturation (duration time =800 ms; inter-pulse delay =10 ms; power level =2 μT) was used. APTw imaging was performed with a multi-offset (offsets =0, ±0.25, ±0.5, ±0.75, ±1, ±1.5, ±2, ±2.5, ±3, ±3.25, ±3.5, ±3.75, ±4, ±4.5, ±5 and ±6 ppm) multi-acquisition protocol. The protocol was repeated eight times at an offset of ±3.5 ppm to increase the signal-to-noise ratio of the APTw images. In addition, an image that did not exert a saturated pulse was acquired for the signal normalisation, and an image that exerted a saturated pulse at the offset of 15.6 ppm was acquired to calculate the conventional MTR value. The detailed imaging parameters were as follows: sensitivity-encoding factor = 2, repetition time (s), 3; echo time (ms), 11; field of view, 240 × 240 mm2; section thickness, 6 mm; matrix, 128 × 128; voxel size, 1.65 × 3.15 × 6.00 mm3. The total acquisition time was 192 s.
Image analysis
The APTw raw data were analysed using interactive data language written in the programme (IDL; Research Systems, Inc., Boulder, CO, USA). First, the normalised saturated signal intensity curve (Ssat/S0, where Ssat and S0 were the signal intensities obtained with and without selective saturation, respectively) as a function of saturation frequency offset, usually called the Z-spectrum, was calculated. The B0 field inhomogeneity effect was corrected, as described previously [18]. To reduce the contributions from conventional magnetisation transfer contrast and direct saturation of bulk water, a B0-corrected Z-spectrum was used to analyse the magnetisation transfer ratio asymmetry (MTRasym) as follows: MTRasym = Ssat(-offset)/S0-Ssat(+offset)/S0. The APTw signal was calculated as MTRasym (3.5 ppm).
Images analysis was performed by two experienced neuroradiologists (L.W. and S.J., who have 11 and 10 years of experience in neuroradiology, respectively). The tumour enhancement type and oedema index (EI) were recorded. Five regions of interest (ROIs) were distributed within the Gd-enhancing tumour area, as well as within the peritumoral brain zone (PBZ; peritumoral T2w hyperintense area, 0.5-2.5 cm from the enhancing tumour area to avoid partial volume contamination) (Fig. 1), based on the Gd-T1WI and T2WI co-registered with the APTw image [32]. Large cystic cavities and haemorrhagic components were always excluded. The size of each ROI was 15 pixels. In addition, the contralateral normal-appearing white matter (CNAWM) was analysed (Fig. 1). For each patient, the APTw values for all ROIs were recorded. Then, the maximum APTw value (APTwmax), minimum APTw value (APTwmin) and mean APTw value (APTwmean) were determined. To reduce the effect of patient age [33] and other potential experimental errors [34], we also recorded the relative APTw (rAPTw = APTw - APTw CNAWM): rAPTwmax, rAPTwmin and rAPTwmean.
Pathological data acquisition
The pathologic images were analysed with image analysis software (Image-Pro Plus, version 6.0, Media Cybernetics, Silver Spring, MD, USA). One neuropathologist, blinded to the MRI features, reviewed the haematoxylin and eosin (H&E)-stained biopsy samples from the tumour core and the PBZ of 39 patients with SBM and 43 patients with GBM. The pathological type and tumour grade were recorded according to 2007 WHO classification of tumours of the CNS. The presence of infiltrating cells in the PBZ was also estimated.
Statistical analysis
Statistical analysis performed was statistical analysis software packages (SPSS19.0 and MedCalc v13.1.2.0). The patient’s gender was compared between SBMs and GBMs using the chi-square test. Comparison among APTwmean values for the tumour core, PBZ and CNAWM was performed using a one-way analysis of variance (ANOVA) test, followed by multiple comparisons using the Tukey test, to analyse the statistical significance of differences. Comparison between patient’s age, APTwCNAWM, APTwmax, APTwmin, APTwmean, rAPTwmax, rAPTwmin or rAPTwmean values for SBMs and GBMs was performed using an independent-samples t-test. Receiver-operating characteristic (ROC) curves were generated for each parameter to assess the areas under the curves (AUCs) and to determine optimal cut-off values according to Youden’s index for the discrimination of SBMs and GBMs. P < 0.05 was considered a statistically significant difference for all tests.
Results
There was no gender difference between the SBM and GBM groups (P = 0.545). The patient age was higher in the SBM group than in the GBM patients (P < 0.001).
Pathological data
In biopsy samples from the PBZ, the tumour cells were present in 29/43 samples; by contrast, 7/39 samples were present in the SBM group.
Comparison of conventional and APTw image features
Forty-five cases of SBMs (45 lesions) were located in the cerebral parenchyma (n = 36) and in the cerebellar hemisphere (n = 9). Eight cases showed mild oedema, 26 cases showed moderate oedema, and 11 cases showed severe oedema. On the Gd-T1WI, tumours showed ring-like (n = 13), nodular (n = 22) or patchy (n = 10) enhancement. The tumour cores showed hyperintensities (relative to the CNAWM) on the APTw images, and the hyperintense areas on APTw images were approximately equal to the lesions shown on the Gd-T1WI. For the 43 cases of GBMs (43 lesions), the lesions were located in the cerebral parenchyma (n = 35), brainstem (n = 2) and cerebellar hemisphere (n = 6). Seven cases showed mild oedema, 30 cases showed moderate oedema, and 6 cases showed severe oedema. In the Gd-T1WI, the tumours showed ring-like (n = 24), nodular (n = 11) or patchy (n = 8) enhancement. Compared with the CNAWM, the lesions identified by the APTw image were larger than those identified by the Gd-T1WI. Figure 2 shows an SBM patient, and Fig. 3 shows a GBM patient.
Quantitative APTw image analysis
The APTw value in the CNAWM was significantly lower in SBMs than in GBMs (0.49% ± 0.18% vs. 0.54% ± 0.14%, P = 0.046). The APTw value in the tumour core of SBMs and GBMs was significantly higher than in the CNAWM (2.76% ± 0.71% vs. 0.49% ± 0.18%, P < 0.001 and 2.94% ± 0.67% vs. 0.54% ± 0.14%, P < 0.001). The APTwmean in the PBZ of SBMs and GBMs was significantly higher than in the CNAWM (1.23% ± 0.23% vs. 0.49% ± 0.18%, P < 0.001 and 1.71% ± 0.34% vs. 0.54% ± 0.14%, P < 0.001). The APTwmax, APTwmin, APTwmean, rAPTwmax, rAPTwmin or rAPTwmean in the tumour core showed significant differences between SBMs and GBMs (P > 0.05). By contrast, all parameters in the PBZ were lower in the SBMs than in the GBMs (P < 0.001) (Table 1 and Fig. 4).
ROC analyses of the APTw parameter values in the PBZ are summarised in Table 2. The APTwmin had the highest AUC of 0.905. When the APTwmin of the PBZ was less than 1.21%, the lesion was diagnosed as an SBM. The sensitivity was 84.4%, the specificity was 86.1%, and the accuracy was 85.2% (Table 2).
Discussion
In this study, the gender distribution of patients with SBMs was not significantly different from that of patients with GBMs, although these two tumour types have been shown to be more common in males. Tan et al. [35] found that there was no age difference between the SBM group and high-grade glioma group, but our result shows the SBM patients were significantly older than the GBM patients. As in a previous study [33, 34], the white matter volume was observed to decline after 50 years of age because of demyelination, and the APTw effect due to the myelin basic protein shifted from the oligodendroglia cytoplasm to the myelin sheath. Therefore, we speculated that this was the reason that the APTw parameter value of the CNAWM was lower in the SBM group.
Whether the tumour core can be reliably discriminated between SBMs and GBMs with conventional MRI, even with several advanced MRI techniques such as DWI, PWI, MRS, DTI and ASL, is still controversial [3, 8, 11, 35,36,37]. Previous studies have shown that APTw MRI can identify the tumour core mainly related to the mobile amide proton content and cell density, which was not relevant to Gd enhancement [16, 18]. This finding is particularly important in the context of the glioma grade, because 10% of patients with glioblastoma may demonstrate non-enhancement on Gd-T1WI [15], which may miss the central nervous system damage and nephrogenic systemic fibrosis caused by Gd deposition during re-examination [38, 39]. Here we use APTw imaging to distinguish between SBMs and GBMs. Compared with the CNAWM, both SBMs and GBMs exhibited tumour core hyperintensity on APTw images. Quantitative APTwmin, APTwmax, APTwmean, rAPTwmin, rAPTwmax or rAPTwmean values of the tumour core were not significantly different (P > 0.05). It is well known that as malignant tumours SBMs and GBMs exhibit rapid cell proliferation in the tumour core [35] and that the cell density and mobile proteins and peptides are higher than those of the CNAWM. However, the difference in proton content between SBMs and GBMs is expected to be negligible. An investigation of the tumour core using APTw MRI cannot provide useful information to distinguishing SBMs from GBMs.
The peritumoral brain zone (PBZ) is defined radiologically as the non-enhancing brain area of several centimetres in width surrounding the tumour in Gd-T1WI. Usually, this area shows hyper-intensity on T2WI and FLAIR images because of vasogenic oedema [40]; as the blood-brain barrier breaks down, capillary permeability increases, a pressure gradient from the vasculature to the extracellular environment is formed, and many intravascular proteins penetrate into the extra-cellular space [41]. In this study, the APTw value in the PBZ of SBMs and GBMs was significantly higher than in the CNAWM (P < 0.001). It is interesting to note that the values of APTwmin, APTwmax, APTwmean, rAPTwmin, rAPTwmax or rAPTwmean in the SBM group were significantly lower than in the GBM group (P < 0.001). In metastasis brain tumours, PBZ T2 hyperintensity mainly reflects vasogenic oedema [7, 35]. In the GBMs, it is hypothesised that specific cells and inflammatory cells infiltrate into the PBZ [40, 42,43,44] and that the PBZ T2 hyperintensity reflects more than vasogenic oedema. Technically, the APTw effect is due to the shift of the amide proton from mobile proteins and peptides to the water proton [12]. In the PBZ of GBMs, other than intravascular proteins, because of the infiltration of tumour cells and inflammatory cells, the tumour-related molecules and inflammatory mediators are also retained in the extra-cellular space of the PBZ [41, 45], and the mobile protein and peptide content may be higher than in SBMs. The pathological examination of PBZ supports this hypothesis. Notably, the APTw value in the PBZ of SBMs was significantly higher than in the CNAWM. We speculate that, as the intravascular proteins penetrate into the extra-cellular space of the PBZ, the amide proton content exceeds that in the CNAWM [41].
According to ROC curve analysis, the APTwmin had the highest AUC (0.905) and accuracy (85.2%) for distinguishing between SBMs and HGGs. For the 88 participants in this study, the accuracy for differentiating SBMs from GBMs was 51.6% (by Y.D., a junior radiologist with 3 years of experience in brain imaging, blinded to the pathology reports, based on conventional MRI sequences) and 79.5% (according to official radiology reports, performed by senior neuro-radiologists in our department). Compared with conventional MRI, protein-based APTW imaging can improve the accuracy for discriminating between SBMs and GBMs.
On conventional MRI images, although glioma cells infiltrate into the PBZ, the blood-brain barrier does not break down, and enhancement is not observed in Gd-T1WI [18]. However, the cell density and mobile proteins and peptides in the PBZ increased; in the PBZ of GBMs, the APTw value was higher closer to the tumour core than the APTw value in the CNAWM; thus, the APTw MRI, which is based on amide protons, may provide new insights into the evaluation of the extent of GBM cell infiltration in the PBZ on a molecular level.
However, this study has several limitations. First, the sample size of the metastasis group mainly involves the metastasis of lung cancer. A larger sample size that includes metastases of more primary cancers is required for more reliable results. Second, the APT-weighted sequence covered only one slice, and the MRI signal changes in other tumour regions could not be evaluated in the present study. Third, in the current study, the voxel size of the APT-weighted sequence was relatively large (due to the small APT effect), which may have led to homogeneous APTw hyperintensities due to the large partial volume effect.
In conclusion, APT-weighted MRI can differentiate between solitary brain metastases and glioblastoma, which indicates that comparisons in APTw parameters in the peritumoral oedema may be useful for differentiating between SBMs and GBMs. The APTwmin has the highest sensitivity, specificity and accuracy. As a safe and completely non-invasive imaging technique, APT-weighted MRI could be a supplement to improve the preoperative diagnosis of SBMs and GBMs in the clinic.
Abbreviations
- GBM:
-
Glioblastoma
- SBM:
-
Solitary brain metastases
- APT:
-
Amide proton transfer
- APTw:
-
APT-weighted
- rAPTw:
-
Relative APTw
- CEST:
-
Chemical exchange-based saturation transfer
- CNAWM:
-
Contralateral normal-appearing white matter
- Gd:
-
Gadolinium
- H&E:
-
Haematoxylin and eosin
- PBZ:
-
Peritumoral brain zone
References
Wang X, Chen JX, Zhou Q et al (2016) Statistical report of central nervous system tumors histologically diagnosed in the Sichuan Province of China from 2008 to 2013: a West China Glioma Center Report. Ann Surg Oncol. doi:10.1245/s10434-016-5410-1
Ostrom QT, Gittleman H, Fulop J et al (2015) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro-Oncology 17:v1–iv62
Blanchet L, Krooshof PW, Postma GJ et al (2011) Discrimination between metastasis and glioblastoma multiforme based on morphometric analysis of MR images. AJNR Am J Neuroradiol 32:67–73
Yuh WT, Engelken JD, Muhonen MG, Mayr NA, Fisher DJ, Ehrhardt JC (1992) Experience with high-dose gadolinium MR imaging in the evaluation of brain metastases. AJNR Am J Neuroradiol 13:335–345
Owonikoko TK, Arbiser J, Zelnak A et al (2014) Current approaches to the treatment of metastatic brain tumours. Nat Rev Clin Oncol 11:203–222
Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507
Lee EJ, Ahn KJ, Lee EK, Lee YS, Kim DB (2013) Potential role of advanced MRI techniques for the peritumoural region in differentiating glioblastoma multiforme and solitary metastatic lesions. Clin Radiol 68:e689–e697
Han CK, Huang SM, Guo JF, Zhuang XJ, Han HW (2015) Use of a high b-value for diffusion weighted imaging of peritumoral regions to differentiate high-grade gliomas and solitary metastases. J Magn Reson Imaging 42:80–86
Abe T, Mizobuchi Y, Sako W et al (2015) Clinical significance of discrepancy between arterial spin labeling images and contrast-enhanced images in the diagnosis of brain tumors. Magn Reson Med Sci 14:313–319
Caivano R, Lotumolo A, Rabasco P et al (2013) 3 Tesla magnetic resonance spectroscopy: cerebral gliomas vs. metastatic brain tumors. Our experience and review of the literature. Int J Neurosci 123:537–543
Mouthuy N, Cosnard G, Abarca-Quinones J, Michoux N (2012) Multiparametric magnetic resonance imaging to differentiate high-grade gliomas and brain metastases. J Neuroradiology Journal de neuroradiologie 39:301–307
Zhou J, Lal B, Wilson DA, Laterra J, van Zijl PC (2003) Amide proton transfer (APT) contrast for imaging of brain tumors. Magn Reson Med 50:1120–1126
Zhou J, Payen JF, Wilson DA, Traystman RJ, van Zijl PC (2003) Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat Med 9:1085–1090
van Zijl PCM, Yadav NN (2011) Chemical exchange saturation transfer (CEST): what is in a name and what Isn't? Magn Reson Med 65:927–948
Jiang SS, Yu H, Wang XL et al (2016) Molecular MRI differentiation between primary central nervous system lymphomas and high-grade gliomas using endogenous protein-based amide proton transfer MR imaging at 3 Tesla. Eur Radiol 26:64–71
Zhou J, Zhu H, Lim M et al (2013) Three-dimensional amide proton transfer MR imaging of gliomas: initial experience and comparison with gadolinium enhancement. J Magn Reson Imaging 38:1119–1128
Togao O, Kessinger CW, Huang G et al (2013) Characterization of lung cancer by amide proton transfer (APT) imaging: an in-vivo study in an orthotopic mouse model. Plos One 8:e77019
Wen ZB, Hu SG, Huang FH et al (2010) MR imaging of high-grade brain tumors using endogenous protein and peptide-based contrast. Neuroimage 51:616–622
Togao O, Hiwatashi A, Yamashita K et al (2016) Grading diffuse gliomas without intense contrast enhancement by amide proton transfer MR imaging: comparisons with diffusion- and perfusion-weighted imaging. Eur Radiol. doi:10.1007/s00330-016-4328-0:1-11
Sakata A, Okada T, Yamamoto A et al (2015) Grading glial tumors with amide proton transfer MR imaging: different analytical approaches. J Neuro-Oncol 122:339–348
Jia G, Abaza R, Williams JD et al (2011) Amide proton transfer MR imaging of prostate cancer: a preliminary study. J Magn Reson Imaging 33:647–654
Klomp DWJ, Dula AN, Arlinghaus LR et al (2013) Amide proton transfer imaging of the human breast at 7T: development and reproducibility. NMR Biomed 26:1271–1277
Dula AN, Arlinghaus LR, Dortch RD et al (2013) Amide proton transfer imaging of the breast at 3 T: Establishing reproducibility and possible feasibility assessing chemotherapy response. Magn Reson Med 70:216–224
Wang J, Weygand J, Hwang KP et al (2016) Magnetic resonance imaging of glucose uptake and metabolism in patients with head and neck cancer. Scientific reports 6:30618
Yuan J, Chen S, King AD et al (2014) Amide proton transfer-weighted imaging of the head and neck at 3 T: a feasibility study on healthy human subjects and patients with head and neck cancer. NMR Biomed 27:1239–1247
Zhou JY, Tryggestad E, Wen ZB et al (2011) Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides. Nat Med 17:130–U308
Ma B, Blakeley JO, Hong X et al (2016) Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas. J Magn Reson Imaging 44:456–462
Tietze A, Blicher J, Mikkelsen IK et al (2014) Assessment of ischemic penumbra in patients with hyperacute stroke using amide proton transfer (APT) chemical exchange saturation transfer (CEST) MRI. NMR Biomed 27:163–174
Tee YK, Harston GWJ, Blockley N et al (2014) Comparing different analysis methods for quantifying the MRI amide proton transfer (APT) effect in hyperacute stroke patients. NMR Biomed 27:1019–1029
Zhao XN, Wen ZB, Huang FH et al (2011) Saturation power dependence of amide proton transfer image contrasts in human brain tumors and strokes at 3 T. Magn Reson Med 66:1033–1041
Li CM, Peng S, Wang R et al (2014) Chemical exchange saturation transfer MR imaging of Parkinson's disease at 3 Tesla. Eur Radiol 24:2631–2639
Zhang Y, Heo HY, Lee DH et al (2016) Selecting the reference image for registration of CEST series. J Magn Reson Imaging 43:756–761
Zhang H, Kang H, Zhao X et al (2016) Amide proton transfer (APT) MR imaging and magnetization transfer (MT) MR imaging of pediatric brain development. Eur Radiol 26:3368–3376
Allen JS, Bruss J, Brown CK, Damasio H (2005) Normal neuroanatomical variation due to age: the major lobes and a parcellation of the temporal region. Neurobiol Aging 26:1245–1260
Tan Y, Wang XC, Zhang H et al (2015) Differentiation of high-grade-astrocytomas from solitary-brain-metastases: comparing diffusion kurtosis imaging and diffusion tensor imaging. Eur J Radiol 84:2618–2624
Crisi G, Orsingher L, Filice S (2013) Lipid and macromolecules quantitation in differentiating glioblastoma from solitary metastasis: a short-echo time single-voxel magnetic resonance spectroscopy study at 3 T. J Comput Assist Tomogr 37:265–271
Lee EJ, terBrugge K, Mikulis D et al (2011) Diagnostic value of peritumoral minimum apparent diffusion coefficient for differentiation of glioblastoma multiforme from solitary metastatic lesions. AJR Am J Roentgenol 196:71–76
Ramalho J, Castillo M, AlObaidy M et al (2015) High signal intensity in globus pallidus and dentate nucleus on unenhanced T1-weighted MR images: evaluation of two linear gadolinium-based contrast agents. Radiology 276:836–844
Collidge TA, Thomson PC, Mark PB et al (2007) Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 245:168–175
Lemee JM, Clavreul A, Aubry M et al (2015) Characterizing the peritumoral brain zone in glioblastoma: a multidisciplinary analysis. J Neuro-Oncol 122:53–61
Oh J, Cha S, Aiken AH et al (2005) Quantitative apparent diffusion coefficients and T2 relaxation times in characterizing contrast enhancing brain tumors and regions of peritumoral edema. J Magn Reson Imaging 21:701–708
Goplen D, Bougnaud S, Rajcevic U et al (2010) Alpha B-Crystallin is elevated in highly infiltrative apoptosis-resistant glioblastoma cells. Am J Pathol 177:1618–1628
Parney IF, Waldron JS, Parsa AT (2009) Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation Journal of neurosurgery 110:572–582
Frieboes HB, Zheng X, Sun CH, Tromberg B, Gatenby R, Cristini V (2006) An integrated computational/experimental model of tumor invasion. Cancer Res 66:1597–1604
Fazi B, Felsani A, Grassi L et al (2015) The transcriptome and miRNome profiling of glioblastoma tissues and peritumoral regions highlights molecular pathways shared by tumors and surrounding areas and reveals differences between short-term and long-term survivors. Oncotarget 6:22526–22552
Acknowledgements
This study was partially supported by grants from National Natural Science Foundation of China (81171322), Guangdong Provincial Natural Science Foundation (2014A030313271, S2012010009114), Guangdong Provincial Science and Technology Project (2014A020212726), Southern Medical University clinical research project (LC2016ZD028) and the National Institutes of Health (R01EB009731, R01CA166171).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Guarantor
The scientific guarantor of this publication is Zhibo Wen, MD.
Conflict of interest
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Funding
This study is partially supported by grants from National Natural Science Foundation of China (81171322), Natural Science Foundation of Guangdong Province (2014A030313271), Guangdong Provincial Science and Technology Project (2014A020212726), Natural Science Foundation of Guangdong Province (S2012010009114), Southern Medical University clinical research project (LC2016ZD028) and the National Institutes of Health (R01EB009731, R01CA166171).
Statistics and biometry
No complex statistical methods were necessary for this article.
Informed consent
Written informed consent was obtained from all subjects (patients) in this study.
Ethical approval
Institutional Review Board approval was obtained.
Methodology
• retrospective
• diagnostic or prognostic study
• performed at one institution
Rights and permissions
About this article
Cite this article
Yu, H., Lou, H., Zou, T. et al. Applying protein-based amide proton transfer MR imaging to distinguish solitary brain metastases from glioblastoma. Eur Radiol 27, 4516–4524 (2017). https://doi.org/10.1007/s00330-017-4867-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-017-4867-z